Loading clinical trials...
Loading clinical trials...
This is a multi-center, 2-part study of AMG 655, AMG 479 or AMG 655-placebo plus gemcitabine as first-line treatment of subjects with metastatic pancreatic cancer. Part 1 is an open-label, dose-escala...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
NantCell, Inc.
NCT07660627 · Esophageal Adenocarcinoma, Gastric Cancer, and more
NCT07656571 · Pancreatic Neoplasms, Pancreatic Cancer
NCT07651358 · Stage I Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, and more
NCT07300150 · Colorectal Cancer, Pancreatic Cancer, and more
NCT01102569 · Pancreatic Cancer
Research Site
Alhambra, California
Research Site
Bakersfield, California
Research Site
Fullerton, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions